Search insightSearch by
Insight by year
Drug Prices and Medical Innovation: A Response to Yu, Helms, and Bach
Reply to Health Affairs blog post
Bates White Partner Richard Manning teamed with Professor Henry Grabowski of Duke University to publish a reply to an earlier Health Affairs Blog post. The authors of the original post suggest that prescription drug prices could be reduced without affecting R&D investments or having other adverse effects. Dr. Manning and his coauthor refute that conclusion and illustrate how it is inconsistent with well-established economic principles and with an extensive literature on the economics of the pharmaceutical industry. They conclude that the original post offers no basis for sound policy making. Read their response here.